28 Lancet, highlighted the possibility of self-testing in suitable patients. 15, 2011 Annals of Internal Medicine found that patients achieved a similar therapeutic INR range if they were tested everyġ2 weeks versus every four weeks. “And if we do that, we have the possibilityĮven patients taking warfarin might not need to visit a clinic or doctor's officeĪs frequently to check their international normalized ratio (INR) levels. “My hope is that with easier therapies, that we can start to carve into that With atrial fibrillation were taking warfarin. He pointed to one research analysis, presented at a 2010Īmerican Heart Association meeting, which found that only 61% of suitable patients Scott Kaatz, DO, MSc, FACP, medical director of the anticoagulation clinics at Henryįord Hospital in Detroit. With the dietary requirements and repeated blood checks involved with warfarin, said These drugs provide new options for patients who are unable or unwilling to comply More expensive, physicians can't check efficacy and compliance, and there's no antidote
New oral anticoagulants don't require checking a patient's INR levels. Other warfarin alternatives also are in the development pipeline, includingĪpixaban (Eliquis), which FDA officials have given a priority review designation. Including the lack of an antidote to reverse bleeding, according to anticoagulationĮxperts. Patients taking the drugs don't need the regularīlood checks required with warfarin, although there is a different set of tradeoffs, Food and Drug Administration (FDA) for use (Xarelto), have been approved by the U.S. Since late 2010, two warfarin alternatives, dabigatran etexilate (Pradaxa) and rivaroxaban Drug options to prevent strokes have expanded, with an emerging cadre of warfarin alternatives,Īlong with some new monitoring recommendations for those prescribed the mainstay anticoagulant.
0 kommentar(er)
